Early clinical study of an intermittent schedule for maytansine (NSC-153858)

R. T. Eagan, J. N. Ingle, J. Rubin, S. Frytak, C. G. Moertel

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Maytansine, an ansa macrolide, was evaluated in an early clinical trial in 40 adult patients with various solid tumors. Severe nausea and vomiting, sometimes associated with watery diarrhea and abdominal cramps, and liver function abnormalities, mainly elevation of serum glutamic-oxaloacetic transaminase levels, together constituted what we considered dose-limiting toxicity. Mild hematologic toxicity (mainly thrombocytopenia), neurotoxicity, and possibly cardiac toxicity were also noted. No antitumor effect was seen. An iv dose of 0.750 mg/m2 on days 1, 3, and 5 (total dose, 2.25 mg/m2) repeated every 4 weeks is recommended for Phase II trials.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalUnknown Journal
Issue number1
StatePublished - Jan 1 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Early clinical study of an intermittent schedule for maytansine (NSC-153858)'. Together they form a unique fingerprint.

Cite this